MannKind Corp
Company Profile
Business description
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Contact
1 Casper Street
DanburyCT06810
USAT: +1 818 661-5000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
592
Stocks News & Analysis
stocks
Australia’s largest gold miner downgraded on a falling gold price
stocks
Cheap ASX share pays a heavy price for NRL rights
stocks
The World Cup stock you’ve never heard of
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.60 | 19.80 | -0.22% |
| CAC 40 | 8,338.97 | 12.35 | 0.15% |
| DAX 40 | 25,067.09 | 51.18 | -0.20% |
| Dow JONES (US) | 52,637.01 | 149.60 | 0.29% |
| FTSE 100 | 10,497.29 | 24.84 | 0.24% |
| HKSE | 24,346.89 | 171.77 | 0.71% |
| NASDAQ | 26,281.61 | 74.72 | 0.29% |
| Nikkei 225 | 67,786.86 | 770.87 | -1.12% |
| NZX 50 Index | 13,764.55 | 21.12 | -0.15% |
| S&P 500 | 7,575.39 | 31.75 | 0.42% |
| S&P/ASX 200 | 8,780.40 | 16.40 | -0.19% |
| SSE Composite Index | 3,971.28 | 24.89 | -0.62% |